Advertisements

Аромазин

Quick links to important sections

Аромазин

Selected form

Advertisements
Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Аромазин

Property Description
Active ingredient Exemestane
Form Oral film-coated tablet
Pharmacological class Aromatase inhibitor (AI)
General use Hormone suppression
Origin Synthetic steroidal compound

What Type of Medicine is Аромазин?

Аромазин is a synthetic, prescription-only medicine classified as a third-generation aromatase inhibitor (AI). Its single active ingredient is Exemestane, which is administered as an oral film-coated tablet. This drug belongs to the specialized class of antineoplastic agents known generally as anti-estrogens, designed to manipulate specific hormonal pathways.

The structure of Exemestane is formally identified as a steroidal compound, meaning its chemical structure is related to natural hormones. This unique origin provides a differentiating factor by facilitating its specific, irreversible mechanism of action.


How Does Аромазин Work at a High Level?

The medicine's high-level function is to create a state of profound estrogen suppression throughout the body by targeting a specific enzyme. As a "suicide inhibitor," Аромазин achieves irreversible inhibition of the aromatase enzyme, which is responsible for producing estrogen in peripheral tissues.

This irreversible bond permanently inactivates the targeted enzyme, which is a distinguishing feature from reversible inhibitors. This ensures a potent, sustained reduction in the body's total circulating estrogen, defining its general use as a powerful agent for modulating hormone levels.


What is the General Therapeutic Purpose of Exemestane?

The overall therapeutic purpose of Exemestane is to counteract hormonal stimulation that can influence certain biological conditions. By effectively and significantly reducing the levels of circulating estrogen, the medicine aims to mitigate the primary hormonal stimuli that drive the growth of specific hormone-responsive cells. This provides a clear, high-level understanding of the drug’s role in creating an environment unfavorable to hormone-dependent processes, which is the required therapeutic objective.

Advertisements

What side effects are possible with Аромазин?

Possible Side Effects and Safety Information

The safety profile of this medicine is derived from data officially documented by government regulatory agencies, classifying potential adverse reactions based on their frequency and the body system affected. Most common effects are understood to be a consequence of the drug's mechanism, which causes profound oestrogen deprivation.

Frequency-Classified Adverse Reactions

Adverse effects are categorized using standard regulatory frequency tiers:

Frequency Classification Examples of Officially Listed Adverse Reactions
Very Common (≥ 1/10) Hot flushes, fatigue, arthralgia (joint pain), headache, insomnia, increased sweating (hyperhidrosis)
Common (≥ 1/100 to < 1/10) Nausea, depression, dizziness, pain in limb, alopecia (hair loss), rash, hypertension, vomiting, lymphedema
Uncommon (≥ 1/1,000 to < 1/100) Somnolence (drowsiness), thromboembolism, gastric ulcer, hepatitis

System-Organ Class Groupings

Adverse reactions are officially grouped into categories such as Musculoskeletal and Connective Tissue Disorders (including joint pain and osteoporosis), Gastrointestinal Disorders (e.g., nausea and abdominal pain), and Vascular Disorders (e.g., hot flushes).

Serious Adverse Reactions and Key Safety Constraints

Official labeling highlights a significant long-term safety concern regarding reduction in Bone Mineral Density (BMD), which increases the risk of osteoporosis and fracture following prolonged exposure. There is also an officially documented risk of cardiac ischemic events.

This medicine is strictly contraindicated for use in pre-menopausal women and during pregnancy or lactation. Furthermore, official regulatory documents note that if effects like somnolence or dizziness occur, the ability to drive or operate machinery may be affected.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose information for Аромазин (Exemestane), based strictly on government regulatory documents.


Documented Overdose Profile

Property Official Regulatory Documentation
Documented Manifestations Single doses up to 800 mg and daily doses up to 600 mg for 12 weeks were generally well tolerated in human studies. A single case of accidental pediatric ingestion noted a transient, resolving leucocytosis (high white blood cell count).
Severe Outcomes No life-threatening adverse events were specifically attributed to high-dose overexposure in human clinical trials.
Specific Antidote There is no specific antidote available to reverse the effects of Exemestane overdose.

Required Emergency Actions

In the event of a suspected overdose, regulatory guidance mandates immediate and supportive medical care:

  • Treatment Approach: Management must be symptomatic and include general supportive care.
  • Monitoring: The patient requires close observation and frequent monitoring of vital signs.
  • When to Seek Urgent Help: If an overdose is suspected, contact a healthcare provider right away or go to the nearest hospital emergency room. For severe signs such as collapse, seizure, difficulty breathing, or inability to be awakened, immediately call emergency medical services.
Advertisements

Therapeutic Uses of Аромазин

The therapeutic use of Exemestane is relevant in the management of specific hormone-sensitive malignancies in postmenopausal women. The medication is generally used to address symptoms related to systemic imbalance caused by estrogen-dependent tumor growth. This medicine is commonly used to help with conditions characterized by periods of heightened symptoms in postmenopausal women with Estrogen Receptor-Positive (ER+) early breast cancer and in situations involving advanced or metastatic ER+ breast cancer.

This provides support that helps ease the overall symptom burden of disease anxiety and may assist with reducing the chance of recurrence, which contributes to long-term management of the disease. In the advanced setting, it may assist in managing the progression of the established disease, supporting patients during difficult symptomatic periods.

“The primary goal of this therapy is to manage the underlying cause of symptoms related to heightened physiological activity, which contributes to long-term symptomatic support.”

Quick Fact: Relief for Symptoms Linked to Conditions Involving Episodic or Fluctuating Manifestations

Exemestane is primarily applied in clinical settings that involve supportive symptom management for symptoms linked to organ-specific functional stress, as well as for conditions where functional stability becomes affected that has progressed. It is commonly used as a planned sequential therapy regimen applied in scenarios where additional management of discomfort is required.

Regulatory References

  1. overview of Exemestane
Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Аромазин (Exemestane)

Official regulatory documents define strict criteria for who can and cannot use Exemestane, focusing primarily on hormonal status and hypersensitivity.

Contraindications and Non-Eligibility

Аромазин is strictly contraindicated in:

  • Premenopausal Women: The medicine is explicitly prohibited for use in women who are premenopausal, including those whose menopausal status is uncertain. Postmenopausal status must be confirmed.
  • Pregnancy and Lactation: Use is prohibited during pregnancy due to the risk of fetal harm and is also contraindicated while breastfeeding.
  • Hypersensitivity: Patients with a known allergy to the active substance, Exemestane, or any tablet component must not use the medicine.

Restricted and Age-Based Use

Population Group Regulatory Status
Postmenopausal Women Approved for use.
Children and Adolescents Use is not recommended as safety and efficacy have not been established.
Severe Hepatic Impairment Requires caution and close supervision due to increased drug exposure.
Severe Renal Impairment Requires caution; no dose adjustment is typically required.
Women of Childbearing Potential Must use effective contraception if postmenopausal status is not confirmed.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific pharmacological and metabolic interactions for exemestane (Aromasin) that impact its use. The interaction profile is structured around two key categories of agents that must be considered before and during treatment.


Documented Interaction Domains

Interaction Domain Practical Implication based on Official Labeling
Strong CYP 3A4 Inducers Co-administration requires a specific dose increase of exemestane (e.g., from 25 mg to 50 mg) to counteract reduced drug exposure.
Estrogen-Containing Agents These agents are contraindicated and must not be co-administered as they interfere with the pharmacologic action of exemestane.

Details of Official Interaction Profile

Concomitant use with strong inducers of the CYP 3A4 enzyme, such as Rifampicin, Phenytoin, Carbamazepine, Phenobarbital, and the herbal product St. John's wort, significantly decreases the plasma concentration of exemestane. This pharmacokinetic interaction mandates an adjustment to the exemestane dose, as stated in the official prescribing information, to maintain therapeutic levels.

Conversely, agents containing estrogens, including hormonal contraceptives and hormone replacement therapy, can compromise the effectiveness of exemestane through pharmacodynamic antagonism. Therefore, their use concurrently with exemestane is strictly restricted by regulatory authorities. Additionally, females of reproductive potential must use effective non-hormonal contraception during therapy and for one month following the final dose.

Advertisements

Mechanism of Action

Aromasin (exemestane) operates as a steroidal, irreversible aromatase inactivator that substantially suppresses estrogen production in peripheral tissues. Its mechanism is described as "suicide inhibition" because the drug molecule acts as a false substrate for the enzyme.

Irreversible Inactivation of Aromatase

The drug is a mechanism-based irreversible inhibitor of the aromatase enzyme (CYP19A1). The molecule forms a covalent bond with the enzyme's active site, permanently neutralizing its function. This molecular-level action initiates the cascade by removing the enzyme's catalytic capability.

Suppression of Estrogen Biosynthesis

This action blocks the final, rate-limiting step where androgens are converted into estrogens. The inhibition of this pathway results in a decrease (typically 85–95%) in circulating plasma estrogen concentrations, primarily affecting production in peripheral sites. This process modulates a major endocrine system by creating a state of hormonal deprivation.

Targeted Physiological Consequence

The substantial systemic reduction in estrogen removes the hormonal stimulus required for estrogen-dependent cellular processes. This leads to the physiological outcome where estrogen-dependent cellular activity is significantly diminished due to the lack of hormonal input. The overall physiological effect is the widespread reduction of the hormonal signal across estrogen-sensitive systems.

Advertisements

Dosage and Administration Information

How to Use Аромазин (Exemestane)

Аромазин is supplied as a 25 mg film-coated tablet and is taken by the oral route. Administration is once daily, and the tablet is taken after a meal to achieve the necessary drug absorption.


Dosing and Administration Patterns

The standard adult dose is 25 mg per day for indications in postmenopausal women. The dose is increased to 50 mg daily in cases where there is simultaneous use of a strong CYP 3A4 inducer (such as rifampicin).

Usage Constraint Instruction Detail
Frequency Once daily.
Timing Must be taken after a meal.
Co-medication Do not take concurrently with estrogen-containing agents (including HRT).

Treatment Duration and Specific Populations

Treatment duration is determined by the clinical scenario. In the adjuvant setting (early disease), the medicine is used as part of a sequential regimen to complete a total of five consecutive years of hormonal therapy. For advanced disease, treatment continues until there is evidence of disease progression. No dose adjustment is required for patients with renal or hepatic impairment, but the medicine is not recommended for use in children or adolescents.


Note on Missed Dose: If a dose is missed, the next tablet is taken at the regularly scheduled time. A double dose is not taken to compensate for a missed one.

Advertisements

Recent Clinical Evidence

Exemestane, branded as Aromasin, is an irreversible, steroidal aromatase inhibitor (AI) that plays a vital role in the hormonal treatment of hormone receptor-positive breast cancer, primarily in postmenopausal women. Recent and long-term clinical data continue to support its efficacy across various settings.

Adjuvant Therapy

Clinical trials, notably the Intergroup Exemestane Study (IES), established Aromasin's benefit in the adjuvant setting (treatment following initial therapy). Long-term follow-up from the IES demonstrated that switching to Aromasin after 2 to 3 years of tamoxifen, for a total of five years of endocrine therapy, significantly improved disease-free survival (DFS) and overall survival compared to completing a full five years of tamoxifen.

More recent combined analyses, such as the TEXT and SOFT trials, have confirmed Aromasin's role, along with ovarian function suppression (OFS), in premenopausal women with high-risk, estrogen receptor-positive early breast cancer. Over a 13-year median follow-up, the combination of exemestane plus OFS showed a sustained, significant improvement in DFS and distant recurrence-free interval compared to tamoxifen plus OFS.

Metastatic Disease and Novel Combinations

Aromasin is also established for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following antiestrogen therapy, such as tamoxifen. In this metastatic setting, clinical studies have shown the combination of exemestane with the targeted agent everolimus to be more effective than exemestane alone for patients who have previously been treated with a nonsteroidal AI.

Safety and Emerging Data

The long-term safety profile of Aromasin is generally consistent with other AIs, which may include side effects such as bone mineral density reduction and joint pain (arthralgia). However, emerging studies are exploring alternative dosing schedules to potentially improve tolerability while maintaining efficacy. For instance, some presurgical trials have investigated an intermittent dosing schedule (e.g., three times per week) to maintain estrogen suppression comparable to daily dosing, which could potentially enhance patient adherence and quality of life.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Аромазин (FAQ)


Q: What is the difference between Аромазин and other aromatase inhibitors?

Official information indicates that Аромазин (exemestane) is a steroidal, irreversible aromatase inactivator. This distinguishes it from other common aromatase inhibitors, which are typically non-steroidal and act as reversible inhibitors. The irreversible nature means the drug permanently neutralizes the aromatase enzyme.


Q: What are the most common side effects people report when starting Аромазин?

According to regulatory documents, the most common side effects reported by patients (affecting 1 in 10 people) are generally linked to estrogen deprivation. These commonly reported effects include hot flushes, fatigue, joint pain (arthralgia), headache, insomnia (difficulty sleeping), and increased sweating.


Q: Is it normal to have joint or bone pain while taking Аромазин?

Yes, joint pain, known medically as arthralgia, is listed in the official product information as a very common adverse reaction. This means it is an effect reported by a significant number of patients, affecting 1 in 10 people.


Q: What are common patient concerns when first starting treatment with Аромазин?

Common patient concerns usually relate to the most frequent side effects listed in official documents. These include managing symptoms like hot flushes, general fatigue or tiredness, and the experience of joint pain, which are all very common effects of the medicine.


Q: What kind of monitoring (blood tests, etc.) is needed while on Аромазин?

Regulatory documents recommend monitoring, especially regarding bone health. It is often advised that patients who have or are at risk of osteoporosis should have a baseline Bone Mineral Density (BMD) assessment and be monitored while on treatment. The assessment of 25-hydroxy vitamin D levels prior to treatment is also routinely recommended.


Q: Is it true that Аромазин can affect bone density?

Yes, official labeling notes that reductions in Bone Mineral Density (BMD) are seen with the use of Аромазин over time. This is considered a significant long-term safety concern that may increase the patient's risk of developing osteoporosis and fracture.


Q: Is hair thinning or loss a common side effect of Аромазин?

Hair loss (alopecia) is listed as a common side effect in the official regulatory documents. This means it is an effect reported by 1 in 100 to < 1 in 10 patients.


Q: Does Аромазин cause weight gain, and if so, how much?

Official regulatory documents list a weight increase as a common side effect. Information regarding the typical amount of weight change is not specifically detailed in the summarized regulatory safety data.


Q: Can Аромазин cause digestive issues like nausea or diarrhea?

Yes, both nausea and vomiting are listed as common side effects in the official product information. Diarrhea is also reported as an occasional (common or uncommon) side effect in some official regulatory reports.


Q: Is breast tenderness a normal side effect when starting Аромазин?

Breast tenderness is not listed among the officially reported very common, common, or uncommon side effects in the main clinical trials. Any new or concerning symptoms should always be reported to a healthcare provider for proper evaluation.


Q: How long does it typically take for Аромазин to start working?

Studies on the drug’s action indicate that it achieves maximal suppression of estrogen in the body with consistent daily dosing. Steady-state plasma levels of the drug are generally reached within seven days of starting treatment.


Q: Can men ever be prescribed Аромазин?

The official and approved use of Аромазин is specifically indicated for postmenopausal women with breast cancer. Use in men for any condition is not an official, labeled indication in regulatory documents.


Q: Does drinking alcohol affect the safety or effectiveness of Аромазин?

Official drug interaction documents do not list a specific contraindication with alcohol. However, regulatory bodies recommend seeking professional guidance regarding the concurrent use of alcohol.


Q: Is it safe to drive or operate machinery while taking Аромазин?

Official labeling advises caution, as side effects such as drowsiness, dizziness, or somnolence (sleepiness) have been reported. If these events occur, the ability to safely drive or operate machinery may be impaired.


Q: Can I take multivitamins while I am on Аромазин?

While specific multivitamins are not contra-indicated, official guidance emphasizes that the use of all other medicines, vitamins, or supplements should be discussed with a doctor or pharmacist. This is especially important for products containing estrogen or St. John's Wort, which are known to interact.


Q: Does Аромазин have an effect on cholesterol levels?

Clinical trial data showed that Аромазин was associated with a greater incidence of hypercholesterolemia (high cholesterol) compared to the comparator drug. Some studies also noted a mean reduction in plasma HDL-cholesterol (the 'good' cholesterol).


Q: Can Аромазин affect my mood or cause depression?

Yes, depression is listed as a common side effect in the official product information. This means it is an effect reported in 1 in 100 to < 1 in 10 patients.


Q: Is there a generic version of Аромазин available?

Yes, the active ingredient in Аромазин, which is exemestane, is available as a generic drug. Generic versions are reviewed and approved by regulatory agencies like the FDA.


Q: What is the typical age group of patients prescribed Аромазин?

Аромазин is indicated for use in postmenopausal women, but there is no explicit age restriction on its use. Official studies have not shown that the medicine’s usefulness is limited in the elderly population.


Q: Is there a link between Аромазин and vision changes?

Some official documents have reported visual disturbances or disturbed vision (such as blurriness) in clinical trials. However, these effects were generally reported as rare side effects.

Advertisements

How should Аромазин be stored and disposed of?

How to Store and Dispose of Aromasin (Exemestane)

Aromasin tablets must be stored according to regulatory requirements to maintain product integrity and safety.

Storage Conditions

Requirement Specification
Temperature Store at controlled room temperature: 20 C to 25 C (68 F to 77 F).
Protection Store in the original container, away from heat, moisture, and direct light. Do not freeze.
Safety Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Aromasin must be disposed of according to local regulatory requirements for pharmaceutical waste. The tablets must not be disposed of by flushing them down a drain or throwing them in the household trash. Patients should consult their pharmacist or local waste disposal service for authorized drug take-back or collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Аромазин found in:

A-Z Index: